Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Fineline Cube Apr 12, 2026
Company Deals

Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline

Fineline Cube Apr 12, 2026
Company Deals

NorrDia Medical Raises RMB 100M+ to Complete Bellco Acquisition – Builds Global Blood Purification Platform

Fineline Cube Apr 12, 2026
Company Deals

Vivatides Therapeutics Closes $54M Series A to Advance Extrahepatic Oligonucleotide Delivery Platform – Led by Qiming Venture Partners

Fineline Cube Apr 12, 2026
Company Deals

C4 Therapeutics and Roche Forge $1B+ DAC Collaboration to Pioneer Degrader-Antibody Conjugates in Oncology

Fineline Cube Apr 10, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Fineline Cube Apr 12, 2026
Company Drug

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC

Fineline Cube Apr 12, 2026
Company Drug

Innovent Biologics’ IBI133 Receives Tacit Approval for Clinical Trial from China’s CDE

Fineline Cube Apr 17, 2024

The Center for Drug Evaluation (CDE) in China has granted tacit clinical trial approval to...

Company Drug

Shionogi’s Xofluza Gains Approval in Taiwan for Pediatric Influenza Treatment and Prophylaxis

Fineline Cube Apr 17, 2024

Shionogi & Co., Ltd, a leading Japanese pharmaceutical company, has announced that it has received...

Company Drug

Kangtai Biological Receives NMPA Approval for 20-Valent Pneumococcal Vaccine Clinical Trial

Fineline Cube Apr 17, 2024

Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601), a leading biopharmaceutical company in China, has...

Company

Boehringer Ingelheim Surpasses Bayer in Pharma Sales with EUR 20.8 Billion in 2023

Fineline Cube Apr 17, 2024

Boehringer Ingelheim, a major German pharmaceutical company, has released its financial report for 2023, announcing...

Company Drug

KPC Pharmaceuticals Gets NMPA Green Light for Clinical Trial on Familial Mediterranean Fever Treatment

Fineline Cube Apr 17, 2024

Yunnan-based KPC Pharmaceuticals Inc., (SHA: 600422) has announced that it has received clinical trial approval...

Company Deals

AbbVie Partners with Medincell for Development of Long-Acting Injectable Therapies

Fineline Cube Apr 17, 2024

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, has entered into a partnership with France-based...

Company Drug

Carvykti CAR-T Therapy Sales Reach $157 Million in Q1 2024, Reports GenScript Subsidiary Legend Biotech

Fineline Cube Apr 17, 2024

GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO) based in China, has...

Company

J&J’s Medical Technology Sector Rises 6.3% YOY Despite China’s VBP Impact

Fineline Cube Apr 17, 2024

Johnson & Johnson (J&J; NYSE: JNJ) has reported its financial results for the first quarter...

Policy / Regulatory

China Unveils 2024 Plan to Combat Fraud in Medical Insurance Funds

Fineline Cube Apr 17, 2024

The National Healthcare Security Administration (NHSA) of China, in conjunction with the Supreme People’s Court,...

Policy / Regulatory

Chinese Authorities Launch Special Plan to Rectify Medical Insurance Fraud and Non-Compliance

Fineline Cube Apr 17, 2024

The National Healthcare Security Administration (NHSA) of China, in collaboration with the Supreme People’s Court,...

Drug Policy / Regulatory

China’s NMPA Releases 79th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Apr 17, 2024

The National Medical Products Administration (NMPA) in China has released the 79th batch of reference...

Company Drug

AstraZeneca’s Imfinzi Shows Sustained Survival Benefit in Advanced Biliary Tract Cancer Trial

Fineline Cube Apr 17, 2024

AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical and biopharmaceutical company, has this week announced 3-year...

Medical Device Policy / Regulatory

China’s NMPA Launches 2024 Medical Device Industry Standard Revision Plan

Fineline Cube Apr 17, 2024

The National Medical Products Administration (NMPA) has unveiled the “2024 Medical Device Industry Standard Revision...

Company Deals

Beijing Airdoc Leads RMB 500 Million Joint Venture to Invest in AI-Powered Healthcare

Fineline Cube Apr 17, 2024

Beijing Airdoc Technology Co., Ltd., a leading artificial intelligence (AI)-powered ophthalmology device company, has announced...

Company Drug

Sirnaomics Receives FDA Feedback on STP705 Development Plan for isSCC Treatment

Fineline Cube Apr 17, 2024

Sirnaomics Ltd (HKG: 2257), a leading biopharmaceutical company focused on the discovery and development of...

Company Drug

China Medical System’s Opzelura Approved in Macau for Vitiligo Treatment

Fineline Cube Apr 17, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that it has received market approval...

Company

Roche China’s Talent and Culture Vice President Chen Yanli Departs for New Opportunities

Fineline Cube Apr 16, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced the departure of Chen Yanli, who...

Company Drug

Easton Pharmaceutical Gets NMPA Nod for Generic Version of Merck KGaA’s Concor

Fineline Cube Apr 16, 2024

Easton Pharmaceutical Co., Ltd (SHA: 688513), based in Chengdu, has announced that it has received...

Company Drug

Sanofi Advances Phase I/II Trial of Trifunctional NK Cell Engager in Blood Cancers

Fineline Cube Apr 16, 2024

Sanofi (NASDAQ: SNY), a French multinational pharmaceutical company, has administered the first dose to a...

Company Drug

Roche’s Columvi Meets Overall Survival Endpoint in Diffuse Large B-Cell Lymphoma Trial

Fineline Cube Apr 16, 2024

Roche (SWX: RO), a leading Swiss pharmaceutical company, has announced that a late-stage clinical trial...

Posts pagination

1 … 356 357 358 … 648

Recent updates

  • Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline
  • Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies
  • Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies
  • Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC
  • Sinocelltech to Raise RMB 900M via Private Placement – Funds Working Capital for Biologics Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System – Expands Global Mitral Regurgitation Pipeline

Company Drug

Henlius Biotech Secures Two New NMPA Approvals for Hanlikang – Expands Rituximab Biosimilar into DLBCL Combination Therapies

Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Company Drug

Konruns Pharma Wins NMPA Approval for KC1036 Phase III in Esophageal Cancer – Multi‑Target TKI Advances in 2L+ ESCC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.